Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme

2 Nov 2023

Abstract excerpt

ABSTRACT Virus-like particles (VLPs) are promising nanotools for the development of subunit vaccines due to high immunogenicity and safety. Herein, we explored the versatile and effective Tag/Catcher-AP205 capsid VLP (cVLP) vaccine platform to address the urgent need for the development of an effective and safe vaccine against gonorrhea. The benefits of this clinically validated cVLP platform include its ability...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Herpesvirus Infections and Treatments
Share to Reproductive tract infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37916806
DOI: 10.1128/iai.00245-23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozymePMID 37916806Read ↗

Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based VaccinesSemantic proximity Read ↗

Polysaccharide Conjugate Vaccines: From Historical Milestones to Future StrategiesSemantic proximity Read ↗

Virus-like particles: flexible platforms for vaccine developmentSemantic proximity Read ↗

Preclinical Evaluation of Novel Conserved <em>Neisseria gonorrhoeae</em> Vaccine Candidates Identified Through Infection-Informed Antigen DiscoverySemantic proximity Read ↗

An mRNA–Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-Resistant <i>Neisseria gonorrhoeae</i>Semantic proximity Read ↗

Recent Progress on the Versatility of Virus-Like ParticlesSemantic proximity Read ↗

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read ↗

Precision-engineering of subunit vaccine particles for prevention of infectious diseasesSemantic proximity Read ↗

The coming of age of virus-like particle vaccinesSemantic proximity Read ↗

Pre-clinical efficacy of a candidate Outer Membrane Vesicle gonococcal vaccine in comparison with 4CMenB.Semantic proximity Read ↗

Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design PlatformSemantic proximity Read ↗

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.